>PARTNERSHIP >A Track Record of Successful Collaborations

A Track Record of Successful Collaborations

Recent Collaboration Highlights

Date	News
March 2012	Obtained FDA approval for peginesatide (OMONTYS), co-developed with Affymax
January 2012	Acquired Intellikine, expanding our oncology portfolio
January 2012	Obtained FDA approval for subcutaneous administration of bortezomib (VELCADE)
September 2011	Completed the acquisition of Nycomed, expanding our therapeutic expertise and strengthening our presence in Europe and emerging markets
June 2011	Formed a partnership with Eli Lilly and Company to market raloxifene (EVISTA) in Korea, Hong Kong, Macau, Malaysia, Philippines, Singapore and Thailand
May 2011	Made an equity investment in Fate Therapeutics, through Takeda Ventures
May 2011	Entered into a partnership with Paladin for the development and commercialization of fomepizole in Japan*
April 2011	Formed a two-year drug discovery collaboration with Heptares on a G protein coupled receptor linked to central nervous system disorders
April 2011	Formed a research collaboration with Samyang Corporation for the discovery of a novel drug delivery system (DDS) platform technology
March 2011	Announced a collaboration with Intra-Cellular Therapies for the development, manufacturing and commercialization of selective PDE1 inhibitors
March 2011	Entered into an agreement with Dainippon Sumitomo Pharma for the development and commercialization of lurasidone (LATUDA) in Europe
March 2011	Launched galantamine (REMINYL) in Japan, in collaboration with Janssen
February 2011	Announced a partnership with Pfizer for the co-promotion of the investigational drug tofacitinib in Japan
January 2011	Formed a 5-year R&D alliance with Kyoto University focused on the discovery of new drug targets and biomarkers for schizophrenia and obesity
January 2011	Entered into a worldwide licensing agreement with Zinfandel Pharmaceuticals for the development and commercialization of the TOMM40 assay